Ikeda Yoshifumi, Tsutsui Kenta, Yamada Yoshihiro, Kato Ritsushi, Muramatsu Toshihiro, Senbonmatsu Takaaki
Department of Cardiology, Saitama Medical University International Medical Center, Saitama 350-1298, Japan.
Department, Research Administration Center, Saitama Medical University, Saitama 350-1298, Japan.
J Clin Med. 2020 Dec 19;9(12):4110. doi: 10.3390/jcm9124110.
The (pro)renin receptor ((P)RR), which evokes renin activity with prorenin, is secreted extracellularly as soluble (P)RR (s(P)RR) and may participate in tissue renin-angiotensin system (RAS) activity in severe heart failure (HF) patients. The aim of this study was to determine whether s(P)RR is an adequate marker in severe HF patients treated with RAS inhibitors, beta-blockers, and tolvaptan. We enrolled 11 patients with severe HF between May 2013 and June 2014. First of all, furosemide of all patients was changed to tolvaptan with hydrochlorothiazide and then the treatment had been changed according to the patient's condition. After 1, 3, 6, and 12 months, the variance of s(P)RR, plasma renin activity (PRA), plasma renin concentration (PRC), brain natriuretic peptide (BNP) and their association was investigated. Furosemide was restarted in five patients and two patients suffered cardiac death. PRA/PRC and s(P)RR were unchanged (PRA: 10.7 ± 13.9 to 12.8 ± 8.5 ng/mL/h; PRC: 347.1 ± 577.5 to 148.3 ± 123.8 pg/mL; s(P)RR: 28.2 ± 19.3 to 33.4 ± 22.4 ng/mL) and had no significant correlations (PRA and s(P)RR: = 0.36; PRC and s(P)RR: = 0.35). There was a significant positive correlation with a high correlation coefficient (CC) between PRA and PRC ( < 0.0001, CC = 0.76), and a negative correlation with weak CC between BNP and s(P)RR ( = 0.01, CC = -0.45). In conclusion, s(P)RR was always high and had no correlations with disease state and PRA/PRC in severe HF patients.
(前)肾素受体((P)RR)可与肾素原共同激发肾素活性,它以可溶性(P)RR(s(P)RR)的形式分泌到细胞外,可能参与重度心力衰竭(HF)患者的组织肾素 - 血管紧张素系统(RAS)活性。本研究的目的是确定s(P)RR在接受RAS抑制剂、β受体阻滞剂和托伐普坦治疗的重度HF患者中是否为一个合适的标志物。我们在2013年5月至2014年6月期间招募了11例重度HF患者。首先,将所有患者的呋塞米换成托伐普坦并加用氢氯噻嗪,然后根据患者情况调整治疗方案。在1、3、6和12个月后,研究s(P)RR、血浆肾素活性(PRA)、血浆肾素浓度(PRC)、脑钠肽(BNP)的变化及其相关性。5例患者重新开始使用呋塞米,2例患者发生心源性死亡。PRA/PRC和s(P)RR无变化(PRA:10.7±13.9至12.8±8.5 ng/mL/h;PRC:347.1±577.5至148.3±123.8 pg/mL;s(P)RR:28.2±19.3至33.4±22.4 ng/mL),且无显著相关性(PRA与s(P)RR:=0.36;PRC与s(P)RR:=0.35)。PRA与PRC之间存在显著正相关且相关系数较高(CC)(<0.0001,CC = 0.76),BNP与s(P)RR之间存在弱负相关且CC较低(=0.01,CC = -0.45)。总之,在重度HF患者中,s(P)RR始终较高,且与疾病状态及PRA/PRC无关。